OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Medicine is 174. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-07-01 to 2024-07-01.)

Article	Citations
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection	3151
Post-acute COVID-19 syndrome	3093
Extrapulmonary manifestations of COVID-19	2224
A global survey of potential acceptance of a COVID-19 vaccine	1839
An inflammatory cytokine signature predicts COVID-19 severity and survival	1824
Attributes and predictors of long COVID	1623
Long-term cardiovascular outcomes of COVID-19	1135
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection	849
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma	831
AI in health and medicine	799
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies	778
A dynamic COVID-19 immune signature includes associations with poor prognosis	737
Digital technologies in the public-health response to COVID-19	714
COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries	681
Seasonal coronavirus protective immunity is short-lasting	598
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies	591
Health systems resilience in managing the COVID-19 pandemic: lessons from 28 countries	584
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies	547
SARS-CoV-2 infection of the oral cavity and saliva	525
Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals	511
Targeting metastatic cancer	508
Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination	492
Immune determinants of COVID-19 disease presentation and severity	491
Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera	490
Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2	489

Symptoms and risk factors for long COVID in non-hospitalized adults	486
Long COVID after breakthrough SARS-CoV-2 infection	485
Clustering and superspreading potential of SARS-CoV-2 infections in Hong Kong	480
Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda	473
Single-cell multi-omics analysis of the immune response in COVID-19	469
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial	466
Biomarkers for neurodegenerative diseases	464
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study	463
Large language models in medicine	450
Phylogenomic characterization and signs of microevolution in the 2022 multi-country outbreak of monkeypox virus	450
Looking beyond COVID-19 vaccine phase 3 trials	448
Long COVID in a prospective cohort of home-isolated patients	446
Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa	443
Understanding COVID-19 vaccine hesitancy	441
Toward personalized treatment approaches for non-small-cell lung cancer	426
Intratumoral heterogeneity in cancer progression and response to immunotherapy	418
Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein	417
Deep learning in histopathology: the path to the clinic	413
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial	404
Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection	402
Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK	394
Four distinct trajectories of tau deposition identified in Alzheimer’s disease	394
Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine	390
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes	383
A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer	380
Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension	375
Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy	373
Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants	372
CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer	372
Brown adipose tissue is associated with cardiometabolic health	365
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial	364
Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19	363
Partial recovery of visual function in a blind patient after optogenetic therapy	360
Rapid pathogen detection by metagenomic next-generation sequencing of infected body fluids	356
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial	354
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas	345
Cellular senescence and senolytics: the path to the clinic	341
Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination	340
Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis	339
Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study	338
Federated learning for predicting clinical outcomes in patients with COVID-19	335
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar	334
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus	333
Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant	333
Modeling COVID-19 scenarios for the United States	333
mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar	327
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial	325
Wearable sensor data and self-reported symptoms for COVID-19 detection	322
Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection	320
Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination	319

Single-cell transcriptomic atlas of the human endometrium during the menstrual cycle	318
Sixteen novel lineages of SARS-CoV-2 in South Africa	318
Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination	305
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial	303
SARS-CoV-2 variants of concern are emerging in India	302
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial	302
mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant	301
Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England	297
Minimum information about clinical artificial intelligence modeling: the MI-CLAIM checklist	291
Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults	288
Characterization of pre-existing and induced SARS-CoV-2-specific CD8+ T cells	286
Magnitude, demographics and dynamics of the effect of the first wave of the COVID-19 pandemic on all-cause mortality in 21 industrialized countries	285
Acute and postacute sequelae associated with SARS-CoV-2 reinfection	283
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial	279
COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence	273
Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination	272
Targeting the HIF2–VEGF axis in renal cell carcinoma	271
Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma	269
Revealing COVID-19 transmission in Australia by SARS-CoV-2 genome sequencing and agent-based modeling	269
Long-term neurologic outcomes of COVID-19	268
Unexplained post-acute infection syndromes	267
Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters	266
Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster	263
Multimodal biomedical AI	260
Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals	259
Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI extension	258
Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and demographics	256
Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial	255
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer	254
Microglial activation and tau propagate jointly across Braak stages	252
Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection	250
Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection	250
Underdiagnosis bias of artificial intelligence algorithms applied to chest radiographs in under-served patient populations	247
Rapid SARS-CoV-2 whole-genome sequencing and analysis for informed public health decision-making in the Netherlands	245
Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures	245
Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom	244
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses	244
How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals	244
Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies	244
A stochastic agent-based model of the SARS-CoV-2 epidemic in France	242
Closed-loop neuromodulation in an individual with treatment-resistant depression	241
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results	241
Responsible use of polygenic risk scores in the clinic: potential benefits, risks and gaps	241
Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy	233
Vaccine development for emerging infectious diseases	232
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade	232
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial	231
A guide to immunotherapy for COVID-19	227
Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)	226
A roadmap to increase diversity in genomic studies	226
A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial	222
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies	222
The distribution of cellular turnover in the human body	222
Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern	217
Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California	216
Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19	216
Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer	215
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma	215
Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial	214
Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes	214
Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial	212
Maturation of the gut microbiome during the first year of life contributes to the protective farm effect on childhood asthma	211
Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma	208
Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2	207
First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland	204
Increased global integration in the brain after psilocybin therapy for depression	203
PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial	202
A Neanderthal OAS1 isoform protects individuals of European ancestry against COVID-19 susceptibility and severity	201
Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial	201
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial	200
Crowding and the shape of COVID-19 epidemics	200
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma	199
Robust breast cancer detection in mammography and digital breast tomosynthesis using an annotation-efficient deep learning approach	199
Misinformation: susceptibility, spread, and interventions to immunize the public	199
Articular cartilage regeneration by activated skeletal stem cells	198
Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study	198
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease	196
Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial	195
Activity-dependent spinal cord neuromodulation rapidly restores trunk and leg motor functions after complete paralysis	194
Global maps of travel time to healthcare facilities	193

Modeling transmission of SARS-CoV-2 Omicron in China	192
Targeting the gut and tumor microbiota in cancer	192
The gut microbiome modulates the protective association between a Mediterranean diet and cardiometabolic disease risk	192
Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial	191
Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1	191
Using a real-world network to model localized COVID-19 control strategies	190
The landscape of mRNA nanomedicine	189
Reporting guidelines for human microbiome research: the STORMS checklist	189
Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma	183
Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge	182
Delayed production of neutralizing antibodies correlates with fatal COVID-19	181
Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial	181
Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2	180
The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology	180
COVID-19 and resilience of healthcare systems in ten countries	179
SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland	177
Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial	176
Impaired meningeal lymphatic drainage in patients with idiopathic Parkinson’s disease	175
An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer	174
TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers	174
COVID-19 dynamics after a national immunization program in Israel	174
Wearable-device-measured physical activity and future health risk	174